Background.
A pacemaker system consists of one or two leads connected to a device that is implanted into a
pocket formed just below the collarbone. This pocket is typically subcutaneous, that is, located just above the
pectoral fascia. Even though the size of pacemakers has decreased markedly, complications due to superficial implants do occur. An alternative technique would be intramuscular placement of the pacemaker device, but there
are no randomized controlled trials (RCTs) to support this approach, which is the rationale for the Placement Of
Cardiac PacemaKEr Trial (POCKET). The aim is to study if intramuscular is superior to subcutaneous placement of
a pacemaker pocket.
Methods.
In October 2016, we started to enroll 200 consecutive patients with an indication for bradycardia pacemaker implantation. Patients are randomized to random block sizes, stratified by age group (cut-off: 65 years)
and sex, and then randomized to either subcutaneous or intramuscular implant. A concealed allocation procedure is employed, using sequentially numbered, sealed envelopes. Pocket site is blinded to the patient and in all
subsequent care. The primary endpoint is patient overall satisfaction with the pocket location at 24 months as
measured using a visual analog scale (VAS) 0-10. Secondary endpoints are: complications, patient-reported satisfaction at 1, 12, and 24 months (overall satisfaction, pain, discomfort, degree of unsightly appearance, movement
problems, and sleep problems due to device).
Conclusions.
POCKET is a prospective interventional RCT designed to evaluate if intramuscular is superior to subcutaneous placement of a bradycardia pacemaker during a two-year follow-up.
Arrhythmia, Complication, Pacemaker, Pocket, Randomized controlled trial
Financial support: Region Gävleborg funded this research project.
Peter Magnusson Cardiology Research Unit Department of Medicine Karolinska Institutet Karolinska University Hospital/Solna SE-171 76 Stockholm, Sweden peter.magnusson@regiongavleborg.se

Trending Topic
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk than the general population. A recent study demonstrated a 2.1% higher stroke rate in the […]
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing and is an integral part of the European Heart Rhythm Association (EHRA) core curriculum for the device specialist.1–6 Left bundle branch ...
Welcome to this issue of Heart International. As ever, we aim to provide our readers with the latest developments, insights, and evidence-based discussions in cardiovascular care. This edition is particularly poignant, as we begin with a heartfelt tribute to an ...
Forty-seven years ago, Andreas Gruentzig introduced ‘percutaneous transluminal coronary angioplasty’ (PTCA) as a new approach to treating symptomatic occlusive coronary artery disease.1 The mechanism of balloon angioplasty (BA) formed the foundation around which newer equipment and technologies were developed, including ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, ...
We are sorry to announce the death of one of our valued editorial board members, Dr Richard Heuser (November 17, 1950–May 23, 2024). Richard R Heuser, MD, FACC, FACP, FESC, MSCAI, was an internationally recognized cardiologist, inventor, educator and author, and was a ...
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1 If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
In this issue of Heart International, we are delighted to present a collection of insightful articles that encompass a wide spectrum of topics within the field of cardiovascular medicine. As we navigate the landscape of cardiovascular disease, heart failure, preventative ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.